Day Two At ODAC: Reviewing Drugs To Treat T-Cell Lymphoma In A Difficult Class
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA appears to have more concerns with Gloucester's HDAC inhibitor Istodax (romidepsin) than with Allos' Folotyn (pralatrexate).